The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Antipsychotic‐induced weight gain in first‐episode psychosis patients: a meta‐analysis of differential effects of antipsychotic medications
Open accessAbstract
Aim: The first‐episode psychosis (FEP) represents a critical period to prevent cardiovascular and metabolic morbidity decades later. Antipsychotic (AP)‐induced weight gain is one modifiable factor in this period. The purpose of this study is to conduct a meta‐analysis of AP‐induced weight and body mass index (BMI) change in FEP. Methods: A comprehensive literature search identified 28 articles that reported data on AP‐specific weight or BMI change in FEP. We conducted a meta‐analysis of short‐ and long‐term mean weight and BMI differences between placebo and AP medications. We also performed subgroup and meta‐regression analysis to examine weight, BMI outcomes and their relationship with location (A sian vs. W estern), sponsorship and baseline weight and BMIs. Results: Compared to placebo, AP‐caused mean weight gain was 3.22 kg and 1.4 points BMI in the short‐term, and 5.30 kg and 1.86 points BMI in the long term. Clinically significant weight gain risk increased about twofold with AP use. Weight gain was associated with duration of AP use. AP medications were associated with more weight gain in Western samples as opposed to Asian samples. Most AP medications were associated with significant body weight gain and BMI increase in FEP patients, except for ziprasidone. Olanzapine and clozapine caused the highest weight gain compared to placebo. Conclusion: Except for ziprasidone, most AP medications were associated with body weight gain and BMI increase in FEP patients. Early and continuing effects of various AP medications on weight gain and BMI increase should be taken into consideration by clinicians.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 1×
“diagnoses,(21) but not to that in chronic schizophrenia samples.(14,26) Notably, the selective and potent D2 blocker haloperidol was shown to be associated with very significant weight gain in FEP but not in chronic schizophrenia patients, which may point to a weight increasing effect that plateaus later.”
ResultAntipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
McGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., A. Hawkins, K., E. Hoffman, R., Preda, A., Epstein, I., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.5.790 · Cited by 556
Self-citationA Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness
Daumit, G. L., Dickerson, F. B., Wang, N.-Y., Dalcin, A., Jerome, G. J., Anderson, C. A. M., Young, D. R., Frick, K. D., Yu, A., Gennusa, J. V., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214530 · Cited by 523
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490 · cited 1×
“Randomized clinical trials(19,20) provided some support for this line of thinking as well as a recent meta-analysis which showed that medication-naïve patients, including first episode but mostly other diagnoses such as post-traumatic stress disorder, depression and dementia, gain weight on first-generation AP agents…”
ResultThe unchanging mortality gap for people with schizophrenia.
Chwastiak, L. A., & Tek, C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61072-2 · Cited by 41
Cited by
Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
Dayabandara, M., Hanwella, R., Ratnatunga, S., Seneviratne, S., Suraweera, C., & de Silva, V. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s113099 · Cited by 367
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1713091 · Cited by 216
Capuzzi, E., Bartoli, F., Crocamo, C., Clerici, M., & Carrà, G. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.03.003 · Cited by 139
Transforming the Treatment of Schizophrenia in the United States: The RAISE Initiative
Dixon, L. B., Goldman, H. H., Srihari, V. H., & Kane, J. M. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084934 · Cited by 112
“Specific approaches include smoking prevention and cessation, counseling and lifestyle modification to prevent or limit weight gain, preferred use of lower-risk antipsychotics (Tek et al. 2015), routine monitoring, and referral to and coordination of access to appropriate medical care.”
BackgroundSelf-citation
Metadata
- Authors
- Tek, C., Kucukgoncu, S., Guloksuz, S., Woods, S. W., Srihari, V. H., & Annamalai, A.
- Venue
- Early Intervention in Psychiatry
- Publisher
- Wiley
- Published
- 2015-05-12
- Volume
- 10
- Issue
- 3
- Pages
- 193-202
- ISSN
- 1751-7885 (ISSN-L)
- 1751-7893
- OpenAlex
- W1584182128
- Cited by
- 173
- References
- 9
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.